ONTX News and Press, Onconova Therapeutics Inc. From 03/23/23

2023-03-23 08:51:05 ET Onconova Therapeutics ( NASDAQ: ONTX ) and Pangea Biomed are collaborating to identify biomarkers of response to Onconova's cancer drug candidate rigosertib. The research partnership will use Pangea's proprietary algorithmic platform ENLIGHT to ...

Collaboration builds off clinical data demonstrating rigosertib’s activity against PLK1 and may inform a precision medicine approach towards rigosertib’s evaluation in new indications Collaboration will leverage ENLIGHT, a pan-cancer response predictor scalable to all canc...

2023-03-16 21:56:17 ET Onconova Therapeutics, Inc. (ONTX) Q4 2022 Earnings Conference Call March 16, 2023, 16:30 ET Company Participants Bruce Mackle - LifeSci Advisors Steven Fruchtman - CEO, President & Director Mark Gelder - Chief Medical Officer Mark ...

2023-03-16 16:08:15 ET Onconova Therapeutics press release ( NASDAQ: ONTX ): FY GAAP EPS of -$0.91 misses by $0.63 . Revenue of $0.23M (flat Y/Y) beats by $0.17M . For further details see: Onconova Therapeutics GAAP EPS of -$0.91 misses by $0.63, revenue ...

NEWTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the twelve month...

NEWTOWN, Pa., March 15, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication of two abstracts that ...

NEWTOWN, Pa., March 09, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release it...

Data suggest rigosertib stimulates an anti-cancer immune response via NLRP3 activation, providing mechanistic support for clinical trials of rigosertib-checkpoint inhibitor combinations Data reveal potential targets engaged by rigosertib to inhibit the RAS-MAPK pathway, the overactivati...

Onconova Therapeutics ( NASDAQ: ONTX ) said on Tuesday a Phase 2 trial testing rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa achieved a complete response of all cancerous skin lesions following four treatment c...

Two of two evaluable participants in an ongoing investigator-sponsored program of rigosertib in RDEB-associated squamous cell carcinoma (SCC) have achieved a complete response of all cancerous skin lesions First evaluable participant has been in complete remission with no signs of metas...